2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
ASCO® 2024 Insights: "Final OS & PFS From the AGO-OVAR 2.29/ENGOT-ov34 Study- Atezolizumab vs. Placebo in Combination With Bevacizumab + Chemo in Recurrent Ovarian Cancer"
By
ecancer
FEATURING
Frederik Marmé
By
ecancer
FEATURING
Frederik Marmé
Comments 0
Login to view comments.
Click here to Login